|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0030705,
umls-concept:C0205179,
umls-concept:C0205314,
umls-concept:C0332173,
umls-concept:C0679622,
umls-concept:C0920321,
umls-concept:C1442457,
umls-concept:C1442466,
umls-concept:C1515672,
umls-concept:C1737200,
umls-concept:C1873068,
umls-concept:C2713007
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-1-18
|
|
pubmed:abstractText |
This phase I trial was conducted to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP23573; MK-8669), a nonprodrug rapamycin analog, in patients with advanced solid malignancies.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BedrosianCamille LCL,
pubmed-author:ChuQuincy SQS,
pubmed-author:FetterlyGerald JGJ,
pubmed-author:GoldstonMichelleM,
pubmed-author:KnowlesHeatherH,
pubmed-author:KreisbergJeffJ,
pubmed-author:MathewsLesleyL,
pubmed-author:MaysTheresaT,
pubmed-author:MitaAlain CAC,
pubmed-author:MitaMonica MMM,
pubmed-author:PatnaikAmitaA,
pubmed-author:RicartAlejandro DAD,
pubmed-author:RiveraVictor MVM,
pubmed-author:RowinskyEric KEK,
pubmed-author:TolcherAnthony WAW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
361-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18202410-Adult,
pubmed-meshheading:18202410-Aged,
pubmed-meshheading:18202410-Antineoplastic Agents,
pubmed-meshheading:18202410-Area Under Curve,
pubmed-meshheading:18202410-Dose-Response Relationship, Drug,
pubmed-meshheading:18202410-Drug Administration Schedule,
pubmed-meshheading:18202410-Female,
pubmed-meshheading:18202410-Humans,
pubmed-meshheading:18202410-Injections, Intravenous,
pubmed-meshheading:18202410-Male,
pubmed-meshheading:18202410-Maximum Tolerated Dose,
pubmed-meshheading:18202410-Middle Aged,
pubmed-meshheading:18202410-Neoplasms,
pubmed-meshheading:18202410-Prognosis,
pubmed-meshheading:18202410-Protein Kinases,
pubmed-meshheading:18202410-Sirolimus,
pubmed-meshheading:18202410-Survival Rate,
pubmed-meshheading:18202410-TOR Serine-Threonine Kinases
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
|
|
pubmed:affiliation |
Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center, San Antonio, TX, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
